Urinary System Pathologies Practice Test

A kidney biopsy provides tissue-level information that directly shapes how a glomerular disease is diagnosed and managed. By examining the glomeruli under light microscopy, along with immunofluorescence and sometimes electron microscopy, it reveals the exact type of glomerular disease (for example, membranous nephropathy, IgA nephropathy, focal segmental glomerulosclerosis, lupus nephritis) and the particular pattern of injury. This histology also shows whether there is active inflammation or newer scarring, which helps distinguish disease that might respond to therapy from irreversible damage. That combination—identifying the specific disease, assessing activity versus chronicity, and guiding treatment decisions—explains why a biopsy most influences management.

A biopsy does not measure glomerular filtration rate directly; GFR is estimated from serum creatinine, age, sex, and body size, not from tissue histology. It is not a purely diagnostic tool with no risk—there are bleeding and other risks, so the decision to biopsy weighs potential benefits against those risks. And it does not replace imaging; imaging provides structural and anatomical information and guides many aspects of care, while biopsy adds the essential histopathologic diagnosis that imaging cannot provide.